Jump to section
To accelrete access to life-saving cell therapies.
There is a significant need for efficient, scalable manufacturing of cell therapies in the biopharmaceutical industry. As demand for advanced treatments like CAR T-cell therapies rises, traditional manufacturing methods often struggle with scalability, high costs, and process failures, limiting patients' access to these lifesaving therapies.
In response, Cellares has developed the CEll Shuttle platform, an automated system designed for high-throughput cell therapy production. The Cell Shuttle can manufacture 16 batches simultaneously, cutting batch costs by up to 50%. By integrating advanced technologies for flow cytometry and cell sorting, Cellares enhances operational efficiency, providing comprehensive solutions that accelerate access to therapies.
Partnering with industry leaders like Kite, Bristol Myers Squibb, and Cabeletta Bio further strengthens its market position, showcasing the platform's potential impact. Along with over $355M in funding and a commercial-scale facility in New Jersey, Cellares is well-prepared to scale operations and meet global demand, positioning itself for future growth in the evolving cell therapy landscape.
Steph
Company Specialist at Welcome to the Jungle
Aug 2023
$255m
SERIES C
May 2021
$82m
SERIES B
This company has top investors
Fabian Gerlinghaus
(Co-Founder & CEO)Graduated from the University of Munich with a Master's Degree in Aerospace Engineering. Prior to co-founding Cellares in 2019, they were the CHief Innovation officer at Synthego.
Data
Other Engineering